Kymera Therapeutics (KYMR) Net Margin (2019 - 2026)
Kymera Therapeutics' (KYMR) quarterly Net Margin came in at 201.47% in Q1 2026, up 9528.0% year-on-year from 2.09% in Q1 2025, and up 93.35% on a QoQ basis from 3030.7% in Q4 2025.
Kymera Therapeutics (KYMR) Net Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Net Margin data on file, last reported at 201.47% in Q1 2026.
- On a quarterly basis, Net Margin rose 9528.0% year-over-year to 201.47% in Q1 2026; TTM through Mar 2026 was 611.96%, a 20288.0% decrease from a year earlier, with the FY2025 full-year figure at 794.04%, down 31847.0% from the prior year.
- Net Margin for Q1 2026 stood at 201.47%, up from 3030.7% in the prior quarter.
- Over the last five years, Net Margin for KYMR reached as high as 30.01% in Q4 2023 and fell as low as 3030.7% in Q4 2025.
- Historically, Net Margin has averaged 883.25% across 5 years, with a median of 450.24% in 2022.
- Across the five-year window, Net Margin surged 131868 bps in 2023 and plunged 207381 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 216.03% in 2022, then jumped by 86 bps to 30.01% in 2023, then slumped by 3089 bps to 956.88% in 2024, then tumbled by 217 bps to 3030.7% in 2025, then surged by 93 bps to 201.47% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 201.47% in Q1 2026, 3030.7% in Q4 2025, and 2973.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - | -201.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -201.47% |
| Dec 31, 2025 | -3,030.70% |
| Sep 30, 2025 | -2,973.05% |
| Jun 30, 2025 | -667.60% |
| Mar 31, 2025 | -296.75% |
| Dec 31, 2024 | -956.88% |
| Sep 30, 2024 | -1,670.33% |
| Jun 30, 2024 | -163.98% |
| Mar 31, 2024 | -472.02% |
| Dec 31, 2023 | -30.01% |
| Sep 30, 2023 | -1,118.17% |
| Jun 30, 2023 | -234.96% |
| Mar 31, 2023 | -432.37% |
| Dec 31, 2022 | -216.03% |
| Sep 30, 2022 | -450.24% |
| Jun 30, 2022 | -349.64% |
| Mar 31, 2022 | -1,751.05% |
| Dec 31, 2021 | -223.00% |
| Sep 30, 2021 | -1,329.11% |
| Jun 30, 2021 | -133.16% |